Diagnosis and treatment of allergic rhinitis in children: Results of the PETRA study

Abstract

Paediatric patients treated by specialists for allergic rhinitis have moderate or severe disease. Symptomatic treatment was extensively prescribed but often did not achieve good disease control. Many specialists preferred a wait-and-see approach before prescribing immunotherapy.

Characteristics of domestic predictors of persistent bronchial asthma in adolescents and allergic rhinitis in children with a distal occlusion

“…Thus, in Italy 24 patients (23.08 %) of 104 examined children with allergic rhinitis had a mild persistent course; this fact is consistent with our data [15]. In Spain, the moderate course of allergic rhinitis had 63% of the examined children, which is 12% less than our data, but the hypersensitivity to domestic dust mites was registered with a higher frequency and was equal to 61.9 % [16]. Silvia de Magalhaes Simoes and co-authors showed that 143 (36 %) children of 397 children with bronchial asthma had intermittent course; 160 (40 %) -mild persistent course; 51 (12.8 %) -persistent moderate course and 43 (10.8%) -persistent severe course of the disease [17].…”

Analysis of comorbidities and therapeutic approach for allergic rhinitis in a pediatric population in Spain

“…These figures are in agreement with previous reports of type of immunotherapy used for AR in Spain but do not fit with recent recommendations and also contrasts with higher use of sublingual immunotherapy in other countries such as France or Italy. The low number of patients treated with specific immunotherapy may be explained by the fact that many specialists prefer to wait and see the evolution of the disease before initiating immunotherapy treatment or because ENT specialists do not tend to prescribe immunotherapy.…”

Knowledge levels related to allergen specific immunotherapy and perspectives of parents whose children were diagnosed with asthma and/or allergic rhinitis in Turkey

“…However, 57% of the patients can experience side effects of these drugs and sufficient symptom control may not be ensured. 11,12 Furthermore, pharmacotherapy may not have an effect on the course of the disease and it is required to have the drugs as long as the patients have the symptoms throughout their life.…”